Journal of tissue engineering and regenerative medicine, 2018-03, Vol.12 (3), p.642-652
2018
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Intradiscal application of a PCLA–PEG–PCLA hydrogel loaded with celecoxib for the treatment of back pain in canines: What's in it for humans?
- Ist Teil von
- Journal of tissue engineering and regenerative medicine, 2018-03, Vol.12 (3), p.642-652
- Ort / Verlag
- England: Hindawi Limited
- Erscheinungsjahr
- 2018
- Quelle
- Wiley Online Library - AutoHoldings Journals
- Beschreibungen/Notizen
- Chronic low back pain is a common clinical problem in both the human and canine population. Current pharmaceutical treatment often consists of oral anti‐inflammatory drugs to alleviate pain. Novel treatments for degenerative disc disease focus on local application of sustained released drug formulations. The aim of this study was to determine safety and feasibility of intradiscal application of a poly(ε‐caprolactone‐co‐lactide)‐b‐poly(ethylene glycol)‐bpoly(ε‐caprolactone‐co‐lactide) PCLA–PEG–PCLA hydrogel releasing celecoxib, a COX‐2 inhibitor. Biocompatibility was evaluated after subcutaneous injection in mice, and safety of intradiscal injection of the hydrogel was evaluated in experimental dogs with early spontaneous intervertebral disc (IVD) degeneration. COX‐2 expression was increased in IVD samples surgically obtained from canine patients, indicating a role of COX‐2 in clinical IVD disease. Ten client‐owned dogs with chronic low back pain related to IVD degeneration received an intradiscal injection with the celecoxib‐loaded hydrogel. None of the dogs showed adverse reactions after intradiscal injection. The hydrogel did not influence magnetic resonance imaging signal at long‐term follow‐up. Clinical improvement was achieved by reduction of back pain in 9 of 10 dogs, as was shown by clinical examination and owner questionnaires. In 3 of 10 dogs, back pain recurred after 3 months. This study showed the safety and effectiveness of intradiscal injections in vivo with a thermoresponsive PCLA–PEG–PCLA hydrogel loaded with celecoxib. In this set‐up, the dog can be used as a model for the development of novel treatment modalities in both canine and human patients with chronic low back pain.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1932-6254eISSN: 1932-7005DOI: 10.1002/term.2483Titel-ID: cdi_proquest_miscellaneous_1903162782
- Format
- –
- Schlagworte
- Animals, Back pain, Back Pain - diagnostic imaging, Back Pain - drug therapy, Back Pain - etiology, Back Pain - veterinary, Biocompatibility, Biocompatible Materials, Celecoxib, Celecoxib - pharmacology, Celecoxib - therapeutic use, Chronic Pain - diagnostic imaging, Chronic Pain - drug therapy, Chronic Pain - etiology, Chronic Pain - veterinary, controlled release, COX-2 inhibitors, Cyclooxygenase 2 - metabolism, Degeneration, Degenerative disc disease, Disease Models, Animal, Dogs, Extracellular Matrix - metabolism, Feasibility studies, Female, Formulations, Hydrogels, Hydrogels - administration & dosage, Hydrogels - chemical synthesis, Hydrogels - chemistry, In vivo methods and tests, Inflammation, Injection, Injections, Subcutaneous, Intervertebral Disc - diagnostic imaging, Intervertebral Disc - drug effects, Intervertebral Disc - pathology, intervertebral disc degeneration, Intervertebral Disc Degeneration - complications, Intervertebral Disc Degeneration - diagnostic imaging, Intervertebral Disc Degeneration - drug therapy, Intervertebral Disc Degeneration - veterinary, Low back pain, Magnetic Resonance Imaging, Medical treatment, Mice, Inbred BALB C, Pain, Patients, Polyesters - administration & dosage, Polyesters - chemical synthesis, Polyesters - chemistry, Polyethylene glycol, Polyethylene Glycols - administration & dosage, Polyethylene Glycols - chemical synthesis, Polyethylene Glycols - chemistry, Regenerative medicine, Safety, Surveys and Questionnaires, Tissue engineering